secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001798749-24-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate reports 2023 net loss $75.5M; Phase 2b topline data for AV-101 in PAH expected June 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments totaled $122.4M at Dec 31, 2023; cash runway expected into 2026.
- Net loss for 2023 was $75.5M compared to $51.5M in 2022; R&D expenses rose to $64.2M from $38.6M.
- Phase 2b portion of IMPAHCT trial enrolled 202 patients; topline data expected in June 2024.
- First patient enrolled in Phase 3 portion of IMPAHCT in November 2023; over 120 clinical sites participating.
- Board expanded with Habib Dable and Donald Santel; Dable appointed Chair in March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/0001798749-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/tmb-20240325x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer